   Leukemias / Lymphomas : High risk Hodgkin lymphoma   Hodgkin
lymphoma is a cancer of the lymph system (a part of the body’s
immune system). The lymph system is made up of tissue throughout
the body that makes and stores infection-fighting cells. The
term “risk” refers to the chance of the cancer coming back after
treatment.  In this study, a commonly used multi-drug
chemotherapy (anti-cancer) regimen for Hodgkin lymphoma will be
used called “OEPA/COPDac”, except that a new drug called
“brentuximab vedotin (also called Adcetris®)” will be
substituted for one of the usual drugs called vincristine,
making this treatment “AEPA/CAPDac”. Brentuximab vedotin is a
drug known as an “antibody-drug conjugate (ADC)”. It is made up
of 2 parts. The first part is a type of antibody (a man-made
version of an immune system protein) that finds and attaches to
the surface of most lymphoma cells. The second part is a
chemotherapy (anti-cancer) drug that stops the cancer cell from
dividing, and kills the cancer cell.  This stu